Evaluation of drug‐drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a physiologically‐based pharmacokinetic model

• मुख्य लेखकों: Ashit Trivedi (लेखक), Winnie Sohn (लेखक), Priyanka Kulkarni (लेखक), Pegah Jafarinasabian (लेखक), Hanze Zhang (लेखक), Marintan Spring (लेखक), Stephen Flach (लेखक), Siddique Abbasi (लेखक), Jan Wahlstrom (लेखक), Edward Lee (लेखक), Sandeep Dutta (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Wiley, 2021-11-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Abstract Omecamtiv mecarbil (OM) is a novel cardiac myosin activator in development for the treatment of heart failure. In vitro, OM is an inhibitor of BCRP. Rosuvastatin, a BCRP substrate, is one of the most commonly prescribed medications in patients with heart failure. The potential for a pharmac...